Search

everythinglearnresearchcommunity

for

Search:↓

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

New compounds were made that are promising for prostate cancer therapy.

Nilotinib can cause skin issues like red bumps and hair loss.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Targeting ornithine decarboxylase can help prevent skin cancer.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Tofacitinib helped a woman regrow hair with no major side effects.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

Glibenclamide slows breast cancer cell growth by stopping cell division.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.